Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.Affymax, Inc. (Nasdaq: AFFY), today announced that it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering.Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass.BSD Medical Corporation (NASDAQ: BSDM) (www.bsdmedical.com) today provided an update on the U.S. Food and Drug Administration’s (FDA) review of the Company's Humanitarian Device Exemption (HDE) marketing submission for the Company’s BSD-2000 Hyperthermia System.Clinical Data, Inc. (NASDAQ: CLDA) today announced that it has enrolled the first patient in its initial Phase III trial of Stedivaze™, a potential best-in-class vasodilator for use in cardiac stress testing.Delcath Systems, Inc. (Nasdaq: DCTH) announced today the closing of its public offering of 9,775,000 shares of common stock priced to the public at $3.60 per share.CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.Depomed, Inc. (NASDAQ:DEPO) announced today that William Callahan has been promoted to vice president, Operations. Mr. Callahan joined Depomed in 2002 and most recently held the position of senior director, Operations.Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.PPD, Inc. (NASDAQ:PPDI) today announced it has signed an agreement to acquire BioDuro LLC, a drug discovery outsourcing company that provides a broad range of integrated services to biopharmaceutical companies. The acquisition will expand PPD’s drug development capabilities in China.Pfizer Inc (NYSE:PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee voted 10 to 1 that the data presented support the safety and effectiveness of its 13-valent pneumococcal conjugate candidate vaccine, Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for the prevention of invasive pneumococcal disease in infants and young children. Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), a specialty pharmaceutical company, today announced the pricing of a public offering of 5,500,000 shares of its common stock.Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today reported data from two nonclinical studies of voreloxin at the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference, which is being held in Boston, MA from November 15-19, 2009.Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today presented new data on the mechanism of action of elesclomol, a first-in-class oxidative stress inducer, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Mass.Tongjitang Chinese Medicines Company (NYSE: TCM) (“Tongjitang” or the “Company”), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced its financial results for the quarter ended September 30, 2009 and the repurchase of ordinary shares in a private transaction.YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that results from a study evaluating nimotuzumab were presented today in a poster at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts.
Drug-maker CytRx Corporation (NASDAQ:CYTR) said its experimental treatment for breast cancer caused a "dramatic destruction" of implanted tumors in an animal model, sending its shares to a new 52-week high.
The company said tumors in animals treated with INNO-206 shrank to about one-half their initial volume by the end of 43 days.
"The market has reacted so much because this compound showed such great efficacy in the animal data and because of the potential for being a very large drug," Rodman & Renshaw analyst Simos Simeonidis said.
Simeonidis expects INNO-206 to be a very large product as it is a pro-drug to doxorubicin, a common cancer treatment that has sales in hundreds of millions of dollars.
A pro-drug is a compound which when taken in gets converted into the active ingredient of a drug.
Shares of the Los Angeles-based company touched a high of $1.24 earlier in the session. They were trading up 12 percent at $1.10 Monday on Nasdaq.
Shares of RXi Pharmaceuticals Corporation(NASDAQ:RXII), 45 percent of which is owned by CytRx, rose as much as 19 percent to $4.20 in the morning session, before shedding some of their gains to trade up nearly 3 percent at $3.62 on Nasdaq.
(Reporting by Vidya L Nathan in Bangalore; Editing by Anil D'Silva)
Below are extreme trades among 18 companies with stock prices under $5 from the BioMedReports.com FDA Calendar, which includes 232 entries as of 7/3/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA fili (...)[More...]
Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response lette (...)[More...]
UP
CytRx Corporation
(CYTR) China Med Technologies Inc
(CMED) Euro Tech Holdings Co Ltd
(CLWT) Anheuser-Busch Companies, Inc
(BUD) Washington Mutual Inc
(WM)
DOWN
99 Cents Only Stores
(NDN) Aluminum Corp China Ltd
(ACH) National Cinemedia Inc
(NCMI) Biomarin Pharmaceutical Inc
(BMRN) Blue Coat Systems Inc
(BCSI)
The Micros Report is the only LIVE IPTV feed dealing with financial news focused expressly on microcap investment analysis, and it streams to every area of the world. Hosted by Mike “the Analyst” Willingham and "Forex" Rick Wright, The Micros Report provides traders, brokers, investors, and market makers the necessary information to trade intelligently in the penny stock market.
Segment 1:
We talked about some of the movers from Friday, July 6, also what looked to be starting a move today, including: SGTL (SigmaTel Inc.)
Segment 2:
In our second segment, we discussed: CYTR (CytRx Corp.), CYBL (Cyberlux Corp.), LYJN (Lyric Jeans, Inc.), SMOU (Stone Mountain), BFTH (Bally Total Fitness)
All News |
Breaking News |
Featured Stories